ClinicalTrials.gg
Not yet recruitingNCT07683312RM-CAR-MRPUpdated Jul 6, 2026

Recurrence Mechanisms of Colorectal Adenoma After Resection and a Multi-Omics Research Protocol

An observational study in Colorectal Adenoma and Carcinoma, sponsored by Zhongshan Hospital Xiamen University. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Zhongshan Hospital Xiamen University · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
30
Sex
All
01

Study summary

We aim to establish a single-cell atlas of primary adenomas, recurrent adenomas, and paired normal mucosa, identify recurrence-associated cell subpopulations and transcriptional pathways, and construct a risk prediction model for recurrence (integrating multi-omics features and clinical variables). Ultimately, we propose a panel of biomarkers that can be used to optimize follow-up strategies and guide potential microbiome-based interventions.

Under the premise of meeting routine clinicopathological requirements, we will collect tissue samples from 30 patients with colorectal adenomas. Each collected adenoma sample will be divided into three equal portions for scRNA-seq, scATAC-seq, and microbiome diversity sequencing, respectively. Two years after sampling, enrolled patients will undergo follow-up colonoscopy. Those in whom adenomas are detected will be classified as the recurrence group, while those without adenomas will be classified as the non-recurrence group. Sequencing data will be jointly analyzed in conjunction with clinical medical records. The tissue specimens obtained will not affect routine diagnosis or treatment outcomes.

Read the detailed description

This study aims to: (1) establish a single-cell atlas of primary adenomas, recurrent adenomas, and paired normal mucosa, and identify recurrence-associated cell subpopulations and transcriptional pathways; (2) construct a recurrence risk prediction model integrating multi-omics features and clinical variables, and propose a panel of biomarkers for optimizing follow-up strategies and guiding potential microbiome-based interventions. The study plans to collect colorectal adenoma tissues from 30 patients who are first diagnosed by endoscopy. Each specimen will be equally divided into three portions for single-cell RNA sequencing (scRNA-seq), single-cell ATAC sequencing (scATAC-seq), and microbiome diversity sequencing. Two years after sampling, all enrolled patients will undergo follow-up colonoscopy; those found to have adenomas will be assigned to the recurrence group, while those without adenomas will be assigned to the non-recurrence group. By integrating multi-omics data for association analysis between the two groups, we aim to elucidate the key drivers of post-polypectomy recurrence, and explore whether there exists an interpretable causal chain linking host epigenetic status, cellular transcriptional programs, and mucosa-associated microbiota that can explain recurrence risk and yield translatable biomarkers. A total of 30 cases will be included. Inclusion criteria: patients with colorectal adenoma confirmed by initial endoscopic examination and pathology. Exclusion criteria: (1) use of antibiotics within the past two weeks; (2) patients without colorectal adenoma; (3) patients with familial adenomatous polyposis; (4) patients with special dietary habits such as vegetarianism, alcoholism, binge eating, or anorexia. Under the premise of meeting routine clinicopathological requirements, 30 colorectal adenoma tissue samples will be collected and each sample will be divided into three equal parts for scRNA-seq, scATAC-seq, and microbiome diversity sequencing. Two years after sampling, patients will undergo follow-up colonoscopy; those with adenomas detected will be classified as the recurrence group, and those without as the non-recurrence group. Through integrated multi-omics correlation analysis, a single-cell integrative atlas of "mucosal microbiota - host epigenome (scATAC) - transcriptome (scRNA)" will be constructed to decipher the key cell states, regulatory elements, and microenvironmental signals underlying post-adenomectomy recurrence, and to establish a multidimensional biomarker panel for risk stratification. Statistical analysis will be performed using SPSS 26.0. Univariate statistical tests will be applied to compare differences between groups. For normally distributed data, ANOVA (for multiple groups) and Student's t-test (for two groups) will be used; for non-normally distributed data, the Kruskal-Wallis H test (for multiple groups) and Mann-Whitney U test (for two groups) will be employed.

02

Conditions studied

  • Colorectal Adenoma and Carcinoma

Browse trials for

03

In context

Carcinoma

736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.

This study's planned enrollment of 30 is below the median of 165 across 129 observational studies indexed under Carcinoma.

Browse Carcinoma studies →

Lead sponsor

Zhongshan Hospital Xiamen University is the lead sponsor of 22 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients who have undergone colonoscopy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with colorectal adenoma confirmed by initial endoscopic examination and pathological diagnosis.

Exclusion criteria

Exclusion Criteria:

Use of antibiotics within the past 2 weeks; Patients without colorectal adenoma; Patients with familial adenomatous polyposis; Patients with special dietary habits, such as vegetarians, alcoholics, binge eaters, or anorexic patients, etc.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
30 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • The study plans to collect colorectal adenoma tissues from 30 patients initially detected by endosco

    The study plans to collect colorectal adenoma tissues from 30 patients initially detected by endoscopy, and perform scRNA-seq, scATAC-seq, and microbiome diversity sequencing on each sample, respectively. Two years after sampling, all enrolled patients will undergo follow-up colonoscopy; those found to have adenomas will be assigned to the recurrence group, while those without adenomas will be assigned to the non-recurrence group. By integrating multi-omics data for association analysis between the recurrence and non-recurrence groups, we aim to investigate the main driving factors of post-polypectomy recurrence, and to explore whether there exists an interpretable causal chain linking host epigenetic status, cellular transcriptional programs, and mucosa-associated microbiota that can explain recurrence risk and yield translatable biomarkers.

06

What researchers measure

Primary outcomes

  1. Multi-Omics Research Protocol on Recurrence Mechanisms After Colorectal Adenoma Resection

    Whether Recurrence Occurred

    Time frame: December 2029

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided — Uncertain research data

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Aug 2029, 38 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2026
First posted
Jul 6, 2026
StartEst.
Jun 27, 2026
Primary completionEst.
Aug 30, 2029
CompletionEst.
Dec 30, 2029
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07683312
Lead sponsor
Zhongshan Hospital Xiamen University
Responsible party
Jianyin Zhou (Chief Physician, Zhongshan Hospital Xiamen University) — Principal investigator
First posted
Jul 6, 2026
Start date
Jun 27, 2026 (estimated)
Primary completion
Aug 30, 2029 (estimated)
Completion
Dec 30, 2029 (estimated)
Last update
Jul 6, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion